



Real-world Treatment Experience of Treatment-naïve People Living with HIV who Initiated Treatment with Single-tablet Dolutegravir/Lamivudine in a Test and Treat Setting in the United States

J Kuretski,¹ C Donovan,² G Harper,³ D Merrill,² K Mycock,³ A Oglesby,² A Metzner,² J Patarroyo²
¹Midway Specialty Care Center, West Palm Beach, FL, USA; ²ViiV Healthcare, Durham, NC, USA; ³Adelphi Real World, Bollington, Cheshire, UK

Presenting author:
Jimena Patarroyo
410 Blackwell Street,
Durham, North Carolina, 27701
jimena.x.patarroyo@viivhealthcare.com
Phone: (+1) 954-829-9818



Key Takeaways

- TANDEM aimed to characterize real-world prescribing behaviors and treatment outcomes of DTG-based 2DR in the United States (US).
- Here we aim to describe the outcomes of those who initiated DTG/3TC in the Test and Treat (T&T) setting.
- After a median follow-up time of 1.3 years, >83% of treatment-naïve PLWH who initiated on DTG/3TC in a T&T setting experienced sustained virological suppression with few treatment discontinuations (<2%), irrespective of T&T status.
- TANDEM supports results from the STAT trial demonstrating DTG/3TC is a feasible, effective and well tolerated regimen when used in real-world T&T settings in treatment-naïve PLWH.

Introduction

- Dolutegravir/ lamivudine (DTG/3TC) is indicated as a two-drug regimen (2DR) for both treatment naïve and virally suppressed People Living With HIV (PLWH) [1].
- Use of DTG/3TC in these populations is supported by a strong recommendation (AI*) from the DHHS Clinical Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, with some exceptions† [2].
- A Test & Treat (T&T) strategy has evolved in order to increase ART initiation rate and improve linkage of PLWH to healthcare systems [3-4].
- The feasibility, efficacy and safety of DTG/3TC use in a T&T setting has been demonstrated in the STAT trial. There is limited evidence with this approach in US-based real-world clinical settings [5].
- Here we describe outcomes of treatment-naïve (TN) PLWH that were initiated on DTG/3TC as part of a T&T strategy, defined as clinician attestation of treatment initiation shortly after diagnosis and in the absence of known lab-values for HIV-1 RNA viral load, CD4+ cell count and/ or HIV-1 resistance mutations.
 - Primary results for the TANDEM study have been presented previously [6-7]. Findings from TN PLWH with HIV RNA viral loads >100,000 copies/mL can be found at Poster 1278 at ID Week 2022.

Methods

- TANDEM was a US-based, retrospective chart review. 24 sites abstracted clinical characteristic, treatment history, and post-initiation outcomes data from medical charts of PLWH who were initiated on DTG/3TC or dolutegravir / rilpivirine (DTG/RPV).
- Analyses were descriptive and no formal hypotheses were tested.
- Missing data were not imputed. Descriptive analyses were performed in IBM® SPSS® Data Collection Survey Reporter v7.5 software.
- Time to event outcomes were calculated using Kaplan-Meier estimators conducted in StataCorp, 2015. Stata statistical software: Release 16 (College Station, TX, StataCorp LP).

Inclusion Criteria

- ≥18 years old;
- Have a diagnosis of HIV-1 infection;
- Have a history of antiretroviral therapy (ART) consisting of the 2DR DTG/3TC or DTG/RPV as a single tablet regimen (STR);
- DTG/3TC cohort:
 - Must have been initiated on or after 1st May 2019 and before 30th September 2020;
 - Upon initiation, PLWH must have been either treatment-naïve (TN) to ART or virologically suppressed (i.e. stable switch [SS]) defined as having HIV-1 RNA <50 copies/mL, on a stable ART regimen for ≥3 months upon DTG-based 2DR initiation.
- Have at least 6 months of clinical follow-up after initiation of DTG-based 2DR which could include time post-discontinuation of either regimen.

*Rating for Recommendations = Strong (A) / Rating of Evidence = Data from randomized controlled trials (I)
†Exceptions in individuals with HIV RNA viral load >500,000 copies/mL, HBV coinfection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available

Results

- From an overall sample of 469 PLWH, 151 received DTG/RPV and 318 received DTG/3TC, of which 126 were TN and 192 were virologically suppressed, switched from previous ART.
 - Almost half (48%) of the TN cohort received DTG/3TC as part of a T&T paradigm (Figure 1), baseline demographics of this cohort are described in Table 1.

Figure 1. Split of DTG/3TC Treatment Naïve (TN) Sub-Cohorts




Table 1. Baseline Demographics of DTG/3TC TN Sub-Cohorts

	T&T (n=61)	Non-T&T (n=62)
Age (years)		
Mean (SD)	34.4 (±9.97)	40.3 (±14.32)
Assigned Sex at Birth, n (%)		
Male	58 (95.1)	50 (80.6)
Current Gender Identity, n (%)		
Cis-male	52 (85.2)	50 (80.6)
Cis-female	3 (4.9)	12 (19.4)
Trans-female	3 (4.9)	0 (0.0)
Race, n (%)		
White/ Caucasian	42 (68.9)	33 (53.2)
Black	12 (19.7)	24 (38.7)
Mixed race	2 (3.3)	1 (1.6)
Pacific Islander	2 (3.3)	0 (0.0)
Asian	1 (1.6)	1 (1.6)
Not specified	2 (3.3)	3 (4.8)
Ethnicity, n (%)		
Hispanic / Latinx	28 (45.9)	20 (32.3)
Current Insurance Coverage, n (%)		
Employer provided/ sponsored insurance	16 (26.2)	17 (27.4)
Privately arranged insurance	14 (23.0)	8 (12.9)
Medicare	1 (1.6)	7 (11.3)
Medicaid	5 (8.2)	17 (27.4)
Health insurance exchange plan	11 (18.0)	5 (8.1)
AIDS Drug Assistance Program (ADAP)	11 (18.0)	8 (12.9)
No insurance coverage	3 (4.9)	0 (0.0)
Started on free sample of DTG/3TC, n (%)	34 (55.7)	6 (9.7)

Acknowledgments: The authors would like to thank the study investigators across each of the 24 US-based sites for their contribution towards the study in abstracting the data from medical charts of PLWH who were initiated on DTG/3TC.

Funding: Adelphi Real World were paid consultants to ViiV Healthcare (study Sponsor) in connection with development of this publication.

Baseline Characteristics


- Clinical characteristics are described in Table 2.
- Relevant treatment considerations were different for the two subgroups.
 - For the T&T subgroup, the main consideration was limited access to healthcare (n=12) and for the non-T&T it was comorbidities (n=10).
- In the T&T subgroup, the most common reasons for initiating DTG/3TC were avoidance of long-term toxicities (42.6%), followed by simplification/streamlining (13.1%) and convenience (11.5%) (Figure 2).

Table 2. Baseline Clinical Characteristics

	T&T (n=61)	Non-T&T (n=62)
Time on DTG/3TC ongoing† (years)		
Median (IQR)	1.3 (0.9, 1.7)	1.2 (0.8, 1.8)
Laboratory values prior to DTG/3TC initiation		
Median CD4 cell count, cells/mm ³ (IQR)	N/A	366.5 (135, 594)
Median HIV viral load, copies/mL (IQR)	N/A	44,522.0 (10,850, 128,814)
Top Relevant Treatment Considerations, n (%)		
Limited access to healthcare	12 (19.7)	3 (4.8)
Mental health issues	8 (13.1)	1 (1.6)
Job instability	6 (9.8)	1 (1.6)
Health insurance issues/ changes	3 (4.9)	4 (6.5)
Comorbidities	2 (3.3)	10 (16.1)
No relevant treatment considerations identified	32 (52.5)	23 (37.1)
Drug Resistance Testing Performed at DTG/3TC initiation, n (%)		
No resistance testing performed	13 (21.3)	20 (32.3)
Resistance testing performed; no resistance detected	35 (57.4)	28 (45.2)
Resistance testing performed; resistance detected	7 (11.5)	13 (21.0)
Information unknown	6 (9.8)	1 (1.6)
Type of Drug Resistance Detected at DTG/3TC Initiation, n (%)	n=7	n=13
NNRTI resistance*	6 (9.8)	10 (16.1)
PI resistance	2 (3.3)	5 (8.1)
NRTI resistance**	0 (0.0)	1 (1.6)
INI resistance***	0 (0.0)	1 (1.6)

†At the time of data abstraction, excludes PLWH who discontinued DTG/3TC, lost to follow-up or treatment status unknown.
*Most common NNRTI mutations detected overall were K103NS (n=6) and E138KAGQ (n=3).
NRTI mutation detected was M41L (n=1); *INI mutation detected was 'Not otherwise specified' (n=1).

Figure 2. Top HCP Reasons for Initiating TN PLWH on DTG/3TC




References: 1. Centro, V and Perno, C. F., *J. Glob. Antimicrob. Resist.*, 2020;20:228-237. 2. US Departments of Health and Human Services. *Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV*. Accessed March 2, 2022. 3. Gibert, C.L. *et al.*, *Fed. Pract.*, 2016;33(3):32-36. 4. Perez-Gonzalez, A. *et al.*, *Microorganisms*, 2022;10(2):433. 5. Rolle, C.P., *et al.*, *AIDS*, 2021;35(12):1957-1965. 6. Schneider, S. *et al.*, IAS Conference 2022, Montreal; Poster # EPB147 7. Blick, G. *et al.*, AMCP Nexus Conference 2022, National Harbor

Virological Outcomes

- At data cut-off, 57 (93.4%) of the T&T subgroup achieved virological suppression, 3 (4.9%) did not, and 1 (1.6%) was still unknown; in the non-T&T subgroup, 59 (95.2%) achieved virological suppression (Figure 3).
- Median (IQR) time to virological suppression was 9.7 weeks (5.8, 17.7) in the T&T subgroup and 10.7 weeks (5.4, 19.3) in the non-T&T subgroup (Table 3).
- Of the 3 individuals in the T&T subgroup who did not achieve viral suppression, 2 remained on DTG/3TC while 1 was switched to bictegravir/emtricitabine/tenofovir alafenamide.
- Virologic rebound occurred in 6 TN PLWH overall, with 1 of these occurring in the T&T subgroup.

Figure 3. Virological Status of T&T & Non-T&T PLWH on DTG/3TC



¹ Virological suppression defined as a HIV-1 viral load of <50 copies/mL.
² Rebound is defined as PLWH who had two consecutive viral load measurements of ≥200 copies/mL after previous reduction to <50 copies/mL.
³ For non-T&T, 0 PLWH remained virologically detectable.

Table 3. Virological Outcomes

	T&T (n=61)	Non-T&T (n=62)
Time to virological suppression following DTG/3TC initiation (weeks)		
Median (IQR)	9.7 (5.8, 17.7)	10.7 (5.4, 19.3)
Time since virological suppression observed (weeks)		
Median (IQR)	59.9 (33.3, 79.3)	48.5 (29.8, 77.6)
% sustaining viral suppression to 24 weeks†	48 (78.7)	45 (72.6)
Discontinuation Status, n (%)		
Discontinued DTG/3TC*	1 (1.6)	0 (0.0)
Ongoing DTG/3TC	60 (98.4)	60 (96.8)
Unknown/ lost to follow-up	0 (0.0)	2 (3.2)

†All had at least 24 weeks of clinical follow-up post-initiation of DTG/3TC; n=3 T&T and n=7 non-T&T PLWH had remained virologically suppressed to data abstraction but had not yet reached 24 weeks suppressed.
*Primary reason for the n=1 discontinuation was due to 'persistent low-level viremia or viral blips'.

Limitations

- TANDEM captured treatment outcomes up to and including virological rebound only; thus, there is no knowledge of outcomes post-rebound in the 6 who rebounded.
- TANDEM did not capture HepB status at baseline.
- Baseline VL was not captured in the T&T group.

Conclusions

- TANDEM included treatment-naïve PLWH initiating onto DTG/3TC as part of a T&T strategy, a population in which there is limited reported real-world evidence.
- After a median follow-up time of 1.3 years, >83% of the treatment-naïve cohort who initiated on DTG/3TC experienced sustained virological suppression with few treatment discontinuations (<2%), irrespective of T&T status.
- TANDEM supports results from the phase IIIb STAT trial demonstrating DTG/3TC is an effective, feasible and well tolerated regimen when used in real-world settings in treatment-naïve PLWH that were initiated as part of a T&T strategy.

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.